Pablo F. Zamudio-Belaunzaran

Calle Vasco De Quiroga 15, Delegación Tlalpan, CP 14080
Mexico, MEX 14080, Mexico

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 82 publications

Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study.

Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study.

Journal: HIV medicine
Published: May 12, 2026

Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges.

Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges.

Journal: The New England journal of medicine
Published: February 18, 2026

Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges.

Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges.

Journal: The New England journal of medicine
Published: February 18, 2026

Semaglutide improves markers of cardiovascular risk in people with HIV.

Semaglutide improves markers of cardiovascular risk in people with HIV.

Journal: AIDS (London, England)
Published: February 10, 2026

Epigenetic Aging and Treatment Response to Semaglutide in the SLIM LIVER Study.

Epigenetic Aging and Treatment Response to Semaglutide in the SLIM LIVER Study.

Journal: Research square
Published: November 19, 2025

A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391).

A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391).

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 07, 2025

Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study.

Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study.

Journal: npj aging
Published: September 23, 2025

The Bounce-Back Effect: What Happens After Cessation of Low-Dose Semaglutide in People with HIV.

The Bounce-Back Effect: What Happens After Cessation of Low-Dose Semaglutide in People with HIV.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: September 17, 2025

The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV.

The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: September 17, 2025

Trends in Incidence and Risk Factors of HIV-Associated Disseminated Histoplasmosis in the Americas: An Observational Cohort Study.

Trends in Incidence and Risk Factors of HIV-Associated Disseminated Histoplasmosis in the Americas: An Observational Cohort Study.

Journal: Journal of the International AIDS Society
Published: September 15, 2025

Sex disparities in geriatric syndromes among people 50 years or older receiving care for HIV infection in Mexico (2012-2017): a cross-sectional, observational study.

Sex disparities in geriatric syndromes among people 50 years or older receiving care for HIV infection in Mexico (2012-2017): a cross-sectional, observational study.

Journal: The journals of gerontology. Series A, Biological sciences and medical sciences
Published: September 09, 2025

Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357.

Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: April 29, 2025
Showing 1-12 of 82

Last Updated: 09/26/2026